A skilled nursing portfolio comprising 5,000 licensed beds across seven states in the Midwest and Southeast has been sold for about $545 million. “The ...

On December 8, 2025, Smith+Nephew announced its new RISE strategy and financial targets for 2028 at its Capital Markets Day in London. The strategy aims to elevate financial and operational ...

Fintel reports that on December 4, 2025, RBC Capital Markets reiterated coverage of Smith & Nephew plc - Depositary Receipt ...

While the proven Zacks Rank places an emphasis on earnings estimates and estimate revisions to find strong stocks, we also know that investors tend to develop their own individual strategies. With ...

Investors interested in stocks from the Medical - Products sector have probably already heard of Smith & Nephew (SNN) and EssilorLuxottica Unsponsored ADR (ESLOY). But which of these two stocks is ...

Smith & Nephew plc is a long-standing company in the medical device sector, focusing on developing and manufacturing internationally. The company has recently received FDA clearance for its AETOS ...

Here at Zacks, we focus on our proven ranking system, which places an emphasis on earnings estimates and estimate revisions, to find winning stocks. But we also understand that investors develop their ...

Smith & Nephew plc (SNN) key stats comparison: compare with other stocks by metrics: valuation, growth, profitability, momentum, EPS revisions, dividends, ratings.

Investors interested in Medical - Products stocks are likely familiar with Smith & Nephew (SNN) and Stryker (SYK). But which of these two stocks presents investors with the better value opportunity ...